Bicakli, Derya Hopanci <br/><br/>
Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315.  [electronic resource] 

 -  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners  Aug 2015 
 - 318-9 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1477-092X 
<br/><br/><label>Standard No.: </label>10.1177/1078155215585051  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant--adverse effects<br/>Female<br/>Humans<br/>Metabolic Syndrome--chemically induced